## **Cinacalcet-D3**

REFERENCES

Cat. No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-70037S C <sub>22</sub> H <sub>19</sub> D <sub>3</sub> F <sub>3</sub> N 360.43 CaSR; Endogenous Metabolite GPCR/G Protein; Metabolic Enzyme/Protease Please store the product under the recommended conditions in the Certificate of Analysis.	HN D D D D
---	--	------------------

affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

et al. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2006 May;69(9):1586-92.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

[2]. Colloton M, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005 Feb;67(2):467-76.;D.A. Bushinsky,

tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA